Oral Antivirals Market

Global Oral Antivirals Market Outlook 

The antiviral drugs are the class of medication used to treat viral infections such as influenza, viral hepatitis, parvovirus infection, herpes virus infections, and human immunodeficiency virus (HIV). The emergence of new viral infections such as picorna virus and coronavirus and particularly, resistance to currently antiviral drugs have led to an increase in the demand for the new antiviral drugs. Many contributing factors have increased the demand for oral antivirals in the market.

According to the UNAIDS statistics, around 38 million people were living with retroviral HIV, and around 1.7 million new cases were found in 2019. While, as of the end of June 2020, around 26 million HIV patients were accessing antiretroviral therapy. Besides, according to the Centers for Disease Control and Prevention (CDC), in 2019 about 13 million flu cases were found.

What was the Impact of the Covid-19 Pandemic on the Growth of the Oral Antivirals Market?

The demand for oral antiviral has been steadily rising as the coronavirus pandemic induced away towards protection and hygiene. To cater for the growing demand for antivirals, the leading manufacturers and the merging players have started to kick the opportunities to tackle the pandemic crisis and shape their position in the competitive oral antivirals market. Government support and manufacturers investment to develop safe and effective novel formulation has projected growth in demand for antivirals in the oral antivirals market.

For instance, in October 2020, USFDA approved the first antiviral drug Veklury (remdesivir) that was authorized under Emergency Use Authorization (EUA). The approval and reissued EUA was granted to Gildead Sciences Inc. Additionally, in June 2020, Glenmark has received approval from the Indian Drug Regulatory authority for manufacturing Favipiravir tablets marketed under the brand Fabiflue for the treatment of mild to moderate coronavirus in India.

Additionally, growing private funding to develop safe and effective formulation has emerged in the market. For instance, in March 2020, the Canadian government granted fund of $214.6 million for coronavirus research.

What are the Key Trends Impacting Growth of the Global Oral Antivirals Market?

The oral antivirals market is rapidly growing in presence of emerging market players and government organizations, to develop novel formulations in the field of biotechnology and life science areas. The growing focus in research & development activities is another trending factor actively adopted by the leading manufacturers and researchers. The new drug approvals to treat viral diseases and fluctuation in the price of the marketed drugs is another key to step to serve lucrative opportunities in the oral antivirals market. For instance, Cipla is expected to launch Favipiravir oral tablet under the brand name of Ciplenza at Rupees 68 per tablet while, FDC Ltd. launched two variants of Favipiravir under the brand names PiFLU and Favenza for Rupees 55 per tablet for both the variants.

The growing shift towards biologics from the therapeutic landscape and growing understanding of molecular mechanism expected to lift the oral antivirals market growth rapidly. The regulatory bodies are recognizing the newly developed product under special drug designation that benefits the vendors that contribute to increasing the sales of oral antiviral drugs fueling the oral antivirals market growth in the coming years.

What are the driving factors that expected to boost the oral antivirals market growth?

The rising prevalence of viral diseases is one of the major factor expected to boost oral antivirals market growth worldwide. Rising investment in research areas to develop an effective treatment solution with ongoing clinical studies expects to propel market growth. The leading companies are entering into mergers and acquisitions to benefit the scope of treatment with new findings like novel immunotherapy drugs or other novel formulations.

Rising large patient population with growing viral disease cases and increasing awareness about the disease are some of the factors influencing the growth of the oral antivirals market. Rising awareness about early diagnosis of disease, increasing healthcare spending in the developing countries and increasing investment by the government and the leading market players are contributing to the growth of the oral antivirals market. The regulatory approvals for special drug designation for treatment, strong R&D pipeline expects to propel the oral antivirals market growth in the coming future.

What are the restraining factors that can hamper the global oral antivirals market growth?

Lack of knowledge to follow the regimen, lack of efficacy due to the first-pass metabolism, rising adverse like nausea, vomiting, rash, fever, gastrointestinal discomfort, or other side effects expected to impede the growth of the oral antivirals market during the forecast period. The lengthy method of drug development and high cost for the study is another restraining factor that can hamper the oral antivirals market growth.

Competitive Landscape

Key players such as

• Novartis AG
• Abbvie Inc.
• GlaxoSmithKline
• Merck & Co.Inc.
• Bristol-Myers Squibb Company
• Mylan N.V.
• Gilead Sciences Inc.
• Janssen Pharmaceuticals Inc.
• Appili Therapeutics
• Boston biotech Atea Pharmaceutical
• others

are actively involved in oral antivirals market.

What strategies are the Key Players adopting to increase their market share in the Oral Antivirals Market?

The established manufacturers are exploring opportunities in developing nations like India, China to enhance their revenue gains by highly investing in research areas to innovate progressive solutions for the oral antivirals market.

The companies are actively focusing on novel drug development, new product launches. The leading companies are actively participating in collaborative agreements and acquisitions to increase their oral antivirals market penetration and shape their position in the leading oral antivirals market. Additionally, the companies are actively entering into strategic distribution agreements to expand their sales footprint worldwide

For instance, in August 2020, Dr Reddy’s generic drug manufacturer launched Avigan (favipiravir) tablets, an antiviral drug that is currently being manufactured by Fujifilm Toyama Chemical Co., a leading Japanese company. The drug was developed to treat mild to moderate Covid-19 patients in India.

Additionally, in October 2020, Roche collaborated with Boston biotech Atea Pharmaceuticals to accelerate the development and manufacturing of antivirals overseas. Under this collaboration, Roche invested $350 million to develop the partial rights to develop an oral antiviral drug with Atea to treat COVID-19.

What are the Key Opportunities in Oral Antivirals Market?

The various pharmaceutical companies are focusing on research areas to capture the unmet needs of the highly effective treatment to provide long-term effective treatment. Concurrently, investments for increasing the production of oral antivirals drugs are exploring opportunities for the key players.

Why North America is dominating the  Oral Antivirals Market?

North America is dominating the oral antivirals market owing to the increasing prevalence of retroviral diseases among the growing c population including the bisexual, men and women. The strong R&D background with increased healthcare expenditure has raised the region to dominate the oral antivirals market. The rising cases of HIV among the growing population have elevated the demand for oral antiviral drugs in the market.

The presence of leading manufacturers like Abbvie, Inc., Gilead Sciences Inc., Merck & Co., Inc. and many other players has uplifted the oral antivirals market by highly investing in research efforts to innovate and develop effective products to meet the global needs. According to the Centers for Disease Control and Prevention (CDC) around 1.2 million people were infected with HIV at the end of 2018 in the U.S. Of those, the gay, bisexual, and other men accounted for 69% of all new HIV diagnoses. HIV continues to have an inconsistent impact on the growing population, particularly in ethnic minorities, racial, gays and bisexual men.

The research report on the oral antivirals market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on the market provides analysis and information according to market segments such as drug class, disease indications, and distribution channels.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico, Brazil, Argetina)
• Europe (Germany, Italy, France, U.K, Spain, Russia, BENELUX)
• East Asia (China, Japan, South Korea)
• South Asia (India, ASEAN)
• Oceania (Australia, New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Turkey)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Key Segments of global oral antivirals market Covered in the Report

Based on type, the oral antivirals market has been segmented as

• Generic
• Branded

Based on drug class, the oral antivirals market has been segmented as

• Nucleoside reverse transcriptase inhibitors (NRTI)
• Neuraminidase inhibitor
• Nucleoside analogues of guanine
• Nucleoside analogues of thymidine
• Protease Inhibitors
• Nucleotide reverse transcriptase inhibitor (NtRTI)
• Combination Drugs
• Others

Based on disease indication, the oral antivirals market has been segmented as

• Influenza
• Hepatitis
• Human Immunodeficiency Virus (HIV)
• Coronavirus
• Others

Based on distribution channel, the oral antivirals market has been segmented as

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the region, the oral antivirals market has been segmented as

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Why branded segment accounted highest share in the Oral Antivirals Market?

The branded medicines gained popularity in oral antivirals market and accounted highest share owing to the higher adoption of the branded medicines over the generic. The growing shift towards branded medicines with a belief to be safer than generic medicines has surge the demand for the branded medicines.

Why the Hepatitis segment dominated the Oral Antivirals Market?

The hepatitis segments gained dominated the oral antivirals market and accounted highest share owing to the rising prevalence of Hepatitis diseases among the growing population that has surged the demand for the oral antiviral drugs.

According to the Nation Institute of Health (NIH) study, about 2.3 billion people are infected with one or more of the hepatitis viruses worldwide. The viral hepatitis results in around 1.4 million fatals each year, HBV and HCV are responsible for about 90% of these deaths, while the remaining 10% of deaths are caused by other hepatitis viruses.